Therapeutic promise of engineered nonsense suppressor tRNAs
Open Access
Abstract
Nonsense mutations change an amino acid codon to a premature termination codon (PTC) generally through a single‐nucleotide substitution. The generation of a PTC results in a defective truncated protein and often in severe forms of disease. Because of the exceedingly high prevalence of nonsense‐associated diseases and a unifying mechanism, there has been a concerted effort to identify PTC therapeutics. Most clinical trials for PTC therapeutics have been conducted with small molecules that promote PTC read through and incorporation of a near‐cognate amino acid. However, there is a need for PTC suppression agents that recode PTCs with the correct amino acid while being applicable to PTC mutations in many different genomic landscapes. With these characteristics, a single therapeutic will be able to treat several disease‐causing PTCs. In this review, we will focus on the use of nonsense suppression technologies, in particular, suppressor tRNAs (sup‐tRNAs), as possible therapeutics for correcting PTCs. Sup‐tRNAs have many attractive qualities as possible therapeutic agents although there are knowledge gaps on their function in mammalian cells and technical hurdles that need to be overcome before their promise is realized.This article is categorized under: RNA Processing > tRNA Processing Translation > Translation RegulationKeywords
Funding Information
- Cystic Fibrosis Foundation (PORTER20F0, LUECK18GO)
- Vertex Pharmaceuticals
This publication has 229 references indexed in Scilit:
- Attenuation of Nonsense-Mediated mRNA Decay Enhances In Vivo Nonsense SuppressionPLOS ONE, 2013
- Regulation of nonsense‐mediated mRNA decayWIREs RNA, 2012
- Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: to die or not to die, that is the questionCurrent Opinion in Genetics & Development, 2011
- Genetically Encoding Unnatural Amino Acids in Neural Stem Cells and Optically Reporting Voltage-Sensitive Domain Changes in Differentiated NeuronsStem Cells, 2011
- Suppression of nonsense mutations as a therapeutic approach to treat genetic diseasesWIREs RNA, 2011
- 3′ processing of eukaryotic precursor tRNAsWIREs RNA, 2010
- Cellular dynamics of tRNAs and their genesFEBS Letters, 2009
- Evolution of Amber Suppressor tRNAs for Efficient Bacterial Production of Proteins Containing Nonnatural Amino AcidsAngewandte Chemie International Edition, 2009
- Production of β‐globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous β039 thalassemia patientsAmerican Journal of Hematology, 2009
- Different aa-tRNAs Are Selected Uniformly on the RibosomeMolecular Cell, 2008